首页 > 最新文献

Kidney & blood pressure research最新文献

英文 中文
The Prognostic Impact of Renal Function Decline during Hospitalization for Heart Failure. 心力衰竭住院期间肾功能下降对预后的影响。
IF 2.8 4区 医学 Q2 Medicine Pub Date : 2024-01-01 Epub Date: 2023-12-23 DOI: 10.1159/000535901
Otto Mayer, Jan Bruthans, Simona Bílková, Jan Filipovský

Introduction: We aimed to evaluate the prognostic impact of renal insufficiency and fluctuation of glomerular filtration observed during hospitalization for heart failure (HF).

Methods: We followed 3,639 patients hospitalized for acute HF and assessed the mortality risk associated with moderate or severe renal insufficiency, either permanent or transient.

Results: After adjustment, severe renal failure defined as estimated glomerular filtration (eGFR) <30 mL/min indicates ≈60% increase in 5-year mortality risk. Similar risk also had patients with only transient decline of eGFR to this range. In contrast, we did not observe any apparent mortality risk attributable to mild/moderate renal insufficiency (eGFR 30-59.9 mL/min), regardless of whether it was transient or permanent.

Conclusion: Even transient severe renal failure during hospitalization indicates poor long-term prognosis of patients with manifested HF. In contrast, only moderate renal insufficiency observed during hospitalization has no additive long-term mortality impact.

背景:评估心力衰竭住院期间观察到的肾功能不全和肾小球滤过率波动对预后的影响评估心力衰竭(HF)住院期间观察到的肾功能不全和肾小球滤过率波动对预后的影响:我们对3636名因急性心力衰竭住院的患者进行了随访,并评估了与中度或重度肾功能不全(永久性或仅为短暂性)相关的死亡风险:经调整后,严重肾功能衰竭定义为估计肾小球滤过率(eGFR):即使在住院期间出现短暂的严重肾功能衰竭,也预示着显性高血压患者的长期预后不佳。相比之下,住院期间观察到的中度肾功能不全不会增加长期死亡率。
{"title":"The Prognostic Impact of Renal Function Decline during Hospitalization for Heart Failure.","authors":"Otto Mayer, Jan Bruthans, Simona Bílková, Jan Filipovský","doi":"10.1159/000535901","DOIUrl":"10.1159/000535901","url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to evaluate the prognostic impact of renal insufficiency and fluctuation of glomerular filtration observed during hospitalization for heart failure (HF).</p><p><strong>Methods: </strong>We followed 3,639 patients hospitalized for acute HF and assessed the mortality risk associated with moderate or severe renal insufficiency, either permanent or transient.</p><p><strong>Results: </strong>After adjustment, severe renal failure defined as estimated glomerular filtration (eGFR) &lt;30 mL/min indicates ≈60% increase in 5-year mortality risk. Similar risk also had patients with only transient decline of eGFR to this range. In contrast, we did not observe any apparent mortality risk attributable to mild/moderate renal insufficiency (eGFR 30-59.9 mL/min), regardless of whether it was transient or permanent.</p><p><strong>Conclusion: </strong>Even transient severe renal failure during hospitalization indicates poor long-term prognosis of patients with manifested HF. In contrast, only moderate renal insufficiency observed during hospitalization has no additive long-term mortality impact.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139032393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum. 勘误。
IF 2.8 4区 医学 Q2 Medicine Pub Date : 2024-01-01 Epub Date: 2024-03-25 DOI: 10.1159/000537701
{"title":"Erratum.","authors":"","doi":"10.1159/000537701","DOIUrl":"10.1159/000537701","url":null,"abstract":"","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140288449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Focus on Upper Urinary Tract Stones Combined with Parenchymal Infiltrative Renal Pelvis Cancer. 聚焦上尿路结石合并肾盂实质性浸润癌
IF 2.8 4区 医学 Q2 Medicine Pub Date : 2024-01-01 Epub Date: 2024-03-12 DOI: 10.1159/000538280
Yue Zhang, Ying Ke, Ai-Xin Qiu, Bo Yang, Chen Shen, Li-Jie Wen, Xiao-Long Xu, Yang Yu, Wei Wang

Introduction: Upper urinary tract stones combined with parenchymal infiltrative renal pelvic cancer are challenging to detect on imaging and to evaluate the differential diagnosis.

Case presentation: The symptoms and diagnoses in three cases of parenchymal infiltrative renal pelvic cancer and upper urinary tract stones that occurred between June 2019 and June 2022 were reviewed. Primary symptoms of lumbar discomfort and hematuria were evident in all 3 patients. Preoperative computed tomography (CT) abdominal imaging revealed that all three cases had hydronephrosis along with renal stones, while the other two cases only had localized hypoenhancement of the renal parenchyma, which was only thought to be limited inflammatory changes in the renal cortex as a result of the combination of renal pelvis infection. After percutaneous nephrolithotomy or ureteroscopic lithotripsy, a combined renal pelvis tumor was discovered in all of these instances. Radical tumor surgery was later performed. One patient who had several tumor metastases passed away 6 months after surgery. A case with multiple metastases was discovered 15 months after surgery and survived with the help of the current chemotherapy. A case with a bladder tumor recurrence was discovered 16 months after surgery and had transurethral bladder tumor electrosurgery and routine bladder perfusion chemotherapy.

Conclusion: Upper urinary tract stones and parenchymal infiltrative pyel carcinoma have atypical imaging, easily confused with infectious diseases. CT or computed tomography urography (CTU) must be considered by urologists. Patients who have a CT with local renal parenchyma density should be suspected of having parenchymal invasive renal pelvis carcinoma; a needle biopsy ought to be performed; and repeat biopsies may be performed if necessary. High-risk individuals need multiple, sufficient biopsies as needed and a comprehensive intraoperative assessment of the renal pelvic mucosa.

导言:上尿路结石合并肾盂实质浸润癌在影像学检查中很难发现,并需要评估鉴别诊断:上尿路结石合并肾实质浸润性肾盂癌在影像学上的发现和鉴别诊断评估具有挑战性:回顾性分析2019年6月至2022年6月期间发生的3例肾盂实质浸润癌合并上尿路结石患者的症状和诊断。三位患者的主要症状均为腰部不适和血尿。术前腹部计算机断层扫描(CT)影像学检查发现,三例患者均有肾积水并伴有肾结石,而另外两例患者仅有肾实质局部低强化,仅认为是合并肾盂感染导致的肾皮质局限性炎性改变。经皮肾镜碎石术或输尿管镜碎石术后,发现所有这些病例都合并有肾盂肿瘤。随后进行了肿瘤根治手术。一名有多处肿瘤转移的患者在术后 6 个月去世。一名患者在术后 15 个月发现多处肿瘤转移,在目前化疗的帮助下存活了下来。一名患者在术后16个月发现膀胱肿瘤复发,接受了经尿道膀胱肿瘤电切术和常规膀胱灌注化疗:结论:上尿路结石和实质性浸润性肾盂癌的影像学表现不典型,容易与感染性疾病混淆。泌尿科医生必须考虑 CT 或计算机断层扫描尿路造影术(CTU)。CT 显示局部肾实质密度的患者应被怀疑为肾实质浸润性肾盂癌;应进行针刺活检;必要时可重复活检。高危患者需要根据需要进行多次、充分的活检,并在术中对肾盂粘膜进行全面评估。
{"title":"Focus on Upper Urinary Tract Stones Combined with Parenchymal Infiltrative Renal Pelvis Cancer.","authors":"Yue Zhang, Ying Ke, Ai-Xin Qiu, Bo Yang, Chen Shen, Li-Jie Wen, Xiao-Long Xu, Yang Yu, Wei Wang","doi":"10.1159/000538280","DOIUrl":"10.1159/000538280","url":null,"abstract":"<p><strong>Introduction: </strong>Upper urinary tract stones combined with parenchymal infiltrative renal pelvic cancer are challenging to detect on imaging and to evaluate the differential diagnosis.</p><p><strong>Case presentation: </strong>The symptoms and diagnoses in three cases of parenchymal infiltrative renal pelvic cancer and upper urinary tract stones that occurred between June 2019 and June 2022 were reviewed. Primary symptoms of lumbar discomfort and hematuria were evident in all 3 patients. Preoperative computed tomography (CT) abdominal imaging revealed that all three cases had hydronephrosis along with renal stones, while the other two cases only had localized hypoenhancement of the renal parenchyma, which was only thought to be limited inflammatory changes in the renal cortex as a result of the combination of renal pelvis infection. After percutaneous nephrolithotomy or ureteroscopic lithotripsy, a combined renal pelvis tumor was discovered in all of these instances. Radical tumor surgery was later performed. One patient who had several tumor metastases passed away 6 months after surgery. A case with multiple metastases was discovered 15 months after surgery and survived with the help of the current chemotherapy. A case with a bladder tumor recurrence was discovered 16 months after surgery and had transurethral bladder tumor electrosurgery and routine bladder perfusion chemotherapy.</p><p><strong>Conclusion: </strong>Upper urinary tract stones and parenchymal infiltrative pyel carcinoma have atypical imaging, easily confused with infectious diseases. CT or computed tomography urography (CTU) must be considered by urologists. Patients who have a CT with local renal parenchyma density should be suspected of having parenchymal invasive renal pelvis carcinoma; a needle biopsy ought to be performed; and repeat biopsies may be performed if necessary. High-risk individuals need multiple, sufficient biopsies as needed and a comprehensive intraoperative assessment of the renal pelvic mucosa.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140110598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multi-Omics Integrated Analysis of the Protective Effect of EZH2 Inhibition in Mice with Renal Ischemia-Reperfusion Injury. 多组学综合分析 EZH2 抑制对肾缺血再灌注损伤小鼠的保护作用
IF 2.8 4区 医学 Q2 Medicine Pub Date : 2024-01-01 Epub Date: 2024-02-18 DOI: 10.1159/000537866
Shanshan Zou, Jianing Chen, Peihui Zhou, Mengzhu Xue, Ming Wu, Li Wang

Introduction: Acute kidney injury (AKI) is a common clinical syndrome associated with high morbidity and mortality. Inhibition of the methyltransferase enhancer of zeste homolog 2 (EZH2) by its inhibitor 3-deazaneplanocin A (3-DZNeP) exerts renal benefits in acute renal ischemia-reperfusion injury (IRI). However, the underlying mechanisms are not completely known. This study aimed to elucidate the pathological mechanism of EZH2 in renal IRI by combination of multi-omics analysis and expression profiling in a public clinical cohort.

Methods: In this study, C57BL/6 J mice were used to establish the AKI model, which were treated with 3-DZNeP for 24 h. Kidney samples were collected for RNA-seq analysis, which was combined with publicly available EZH2 chromatin immunoprecipitation sequencing (ChIP-seq) data of mouse embryonic stem cell for a joint analysis to identify differentially expressed genes. Several selected differentially expressed genes were verified by quantitative PCR. Finally, single-nucleus sequencing data and expression profiling in public clinical datasets were used to confirm the negative correlation of the selected genes with EZH2 expression.

Results: 3-DZNeP treatment significantly improved renal pathology and function in IRI mice. Through RNA-seq analysis combined with EZH2 ChIP-seq database, 162 differentially expressed genes were found, which might be involved in EZH2-mediated pathology in IRI kidneys. Four differential expressed genes (Scd1, Cidea, Ghr, and Kl) related to lipid metabolism or cell growth were selected based on Gene Ontology and Kyoto Encyclopedia of Genes and Genome enrichment analysis, which were validated by quantitative PCR. Data from single-nucleus RNA sequencing revealed the negative correlation of these four genes with Ezh2 expression in different subpopulations of proximal tubular cells in IRI mice in a different pattern. Finally, the negative correlation of these four genes with EZH2 expression was confirmed in patients with AKI in two clinical datasets.

Conclusions: Our study indicates that Scd1, Cidea, Ghr, and Kl are downstream genes regulated by EZH2 in AKI. Upregulation of EZH2 in AKI inhibits the expression of these four genes in a different population of proximal tubular cells to minimize normal physiological function and promote acute or chronic cell injuries following AKI.

简介急性肾损伤(AKI)是一种常见的临床综合征,发病率和死亡率都很高。通过抑制剂 3-DZNeP(3-Deazaneplanocin A)抑制 Zeste 同源体增强子 2(EZH2)的甲基转移酶,可在急性肾缺血再灌注损伤(IRI)中对肾脏产生益处。然而,其潜在机制尚不完全清楚。本研究旨在通过多组学分析和表达谱分析,阐明EZH2在肾脏IRI中的病理机制:本研究采用C57BL/6J小鼠建立急性肾损伤模型,用3-DZNeP处理24小时。收集肾脏样本进行RNA-seq分析,并结合公开的小鼠胚胎干细胞EZH2-ChIP-seq数据进行联合分析,以确定差异表达基因。通过定量 PCR 验证了几个选定的差异表达基因。最后,利用单核测序数据和公共临床数据集的表达谱分析证实了所选基因与EZH2表达的负相关性:结果:3-DZNeP治疗能明显改善IRI小鼠的肾脏病理和功能。通过RNA-seq分析和EZH2 ChIP-seq数据库,发现了162个差异表达基因,这些基因可能参与了EZH2介导的IRI肾脏病理变化。根据GO和KEGG富集分析,筛选出4个与脂质代谢或细胞生长相关的差异表达基因(Scd1、Cidea、Ghr和Kl),并通过定量PCR进行了验证。snRNA-seq数据显示,在IRI小鼠近端肾小管细胞的不同亚群中,这四个基因与Ezh2的表达呈不同模式的负相关。最后,在两个临床数据集中,这四个基因与急性肾损伤患者中 EZH2 的表达呈负相关:我们的研究表明,Scd1、Cidea、Ghr 和 Kl 是 EZH2 在 AKI 中调控的下游基因。AKI中EZH2的上调抑制了这四个基因在不同近端肾小管细胞群中的表达,从而最大限度地降低了正常生理功能,并促进了急性肾损伤后的急性或慢性细胞损伤。
{"title":"Multi-Omics Integrated Analysis of the Protective Effect of EZH2 Inhibition in Mice with Renal Ischemia-Reperfusion Injury.","authors":"Shanshan Zou, Jianing Chen, Peihui Zhou, Mengzhu Xue, Ming Wu, Li Wang","doi":"10.1159/000537866","DOIUrl":"10.1159/000537866","url":null,"abstract":"<p><strong>Introduction: </strong>Acute kidney injury (AKI) is a common clinical syndrome associated with high morbidity and mortality. Inhibition of the methyltransferase enhancer of zeste homolog 2 (EZH2) by its inhibitor 3-deazaneplanocin A (3-DZNeP) exerts renal benefits in acute renal ischemia-reperfusion injury (IRI). However, the underlying mechanisms are not completely known. This study aimed to elucidate the pathological mechanism of EZH2 in renal IRI by combination of multi-omics analysis and expression profiling in a public clinical cohort.</p><p><strong>Methods: </strong>In this study, C57BL/6 J mice were used to establish the AKI model, which were treated with 3-DZNeP for 24 h. Kidney samples were collected for RNA-seq analysis, which was combined with publicly available EZH2 chromatin immunoprecipitation sequencing (ChIP-seq) data of mouse embryonic stem cell for a joint analysis to identify differentially expressed genes. Several selected differentially expressed genes were verified by quantitative PCR. Finally, single-nucleus sequencing data and expression profiling in public clinical datasets were used to confirm the negative correlation of the selected genes with EZH2 expression.</p><p><strong>Results: </strong>3-DZNeP treatment significantly improved renal pathology and function in IRI mice. Through RNA-seq analysis combined with EZH2 ChIP-seq database, 162 differentially expressed genes were found, which might be involved in EZH2-mediated pathology in IRI kidneys. Four differential expressed genes (Scd1, Cidea, Ghr, and Kl) related to lipid metabolism or cell growth were selected based on Gene Ontology and Kyoto Encyclopedia of Genes and Genome enrichment analysis, which were validated by quantitative PCR. Data from single-nucleus RNA sequencing revealed the negative correlation of these four genes with Ezh2 expression in different subpopulations of proximal tubular cells in IRI mice in a different pattern. Finally, the negative correlation of these four genes with EZH2 expression was confirmed in patients with AKI in two clinical datasets.</p><p><strong>Conclusions: </strong>Our study indicates that Scd1, Cidea, Ghr, and Kl are downstream genes regulated by EZH2 in AKI. Upregulation of EZH2 in AKI inhibits the expression of these four genes in a different population of proximal tubular cells to minimize normal physiological function and promote acute or chronic cell injuries following AKI.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139900181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum Phospholipase A2 Receptor Antibody Is Associated with Thrombogenesis in Patients with Idiopathic Membranous Nephropathy. 血清磷脂酶 A2 受体抗体与特发性膜性肾病患者的血栓形成有关。
IF 2.3 4区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 Epub Date: 2024-06-12 DOI: 10.1159/000539437
Qinling Zhang, Guiling Liu

Introduction: Patients with idiopathic membranous nephropathy (IMN) are particularly susceptible to thromboembolism (TE). The phospholipase A2 receptor (PLA2R) antibody (Ab) has been indicated to work as an independent risk predictor for venous TE in IMN. This study aimed to further explore the predictive value of PLA2R Ab for both venous and arterial TE in IMN patients.

Methods: A total of 91 IMN patients were retrospectively selected and divided into anti-PLA2R-positive or anti-PLA2R-negative groups according to the anti-PLA2R Ab titer (cutoff: 20 RU/mL). Serum PLA2R Abs were estimated using ELISA. Anti-PLA2R-positive IMN patients were further assigned into two groups based on the presence or absence of TE.

Results: Twelve (18.18%) IMN patients with anti-PLA2R positivity had TE, including both venous and arterial TE. No TE occurred in the anti-PLA2R-negative group. IMN patients in the anti-PLA2R-positive group had significantly higher levels of total cholesterol and low-density lipoprotein than those in the anti-PLA2R-negative group. No significant difference was observed in the anti-PLA2R Ab titer between patients with and without TE. Patients with TE were significantly older than those without TE.

Conclusion: This study demonstrates that the positive status of anti-PLA2R Abs contributes to thrombosis formation in IMN.

导言:特发性膜性肾病(IMN)患者特别容易发生血栓栓塞(TE)。磷脂酶 A2 受体(PLA2R)抗体(Ab)被认为是特发性膜性肾病静脉血栓栓塞症的独立风险预测因子。本研究旨在进一步探讨 PLA2R 抗体对 IMN 患者静脉和动脉 TE 的预测价值:方法:回顾性筛选出 91 例 IMN 患者,根据抗 PLA2R Ab 滴度(临界值:20 RU/mL)将其分为抗 PLA2R 阳性组和抗 PLA2R 阴性组。血清 PLA2R 抗体用酶联免疫吸附法估算。根据是否存在 TE,抗-PLA2R 阳性的 IMN 患者被进一步分为两组:12例(18.18%)抗PLA2R阳性的IMN患者出现TE,包括静脉和动脉TE。抗-PLA2R阴性组未出现TE。抗-PLA2R 阳性组 IMN 患者的总胆固醇和低密度脂蛋白水平明显高于抗-PLA2R 阴性组。抗PLA2R抗体滴度在有TE和无TE的患者之间未观察到明显差异。有TE的患者年龄明显大于无TE的患者:本研究表明,抗PLA2R抗体阳性是IMN血栓形成的原因之一。
{"title":"Serum Phospholipase A2 Receptor Antibody Is Associated with Thrombogenesis in Patients with Idiopathic Membranous Nephropathy.","authors":"Qinling Zhang, Guiling Liu","doi":"10.1159/000539437","DOIUrl":"10.1159/000539437","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with idiopathic membranous nephropathy (IMN) are particularly susceptible to thromboembolism (TE). The phospholipase A2 receptor (PLA2R) antibody (Ab) has been indicated to work as an independent risk predictor for venous TE in IMN. This study aimed to further explore the predictive value of PLA2R Ab for both venous and arterial TE in IMN patients.</p><p><strong>Methods: </strong>A total of 91 IMN patients were retrospectively selected and divided into anti-PLA2R-positive or anti-PLA2R-negative groups according to the anti-PLA2R Ab titer (cutoff: 20 RU/mL). Serum PLA2R Abs were estimated using ELISA. Anti-PLA2R-positive IMN patients were further assigned into two groups based on the presence or absence of TE.</p><p><strong>Results: </strong>Twelve (18.18%) IMN patients with anti-PLA2R positivity had TE, including both venous and arterial TE. No TE occurred in the anti-PLA2R-negative group. IMN patients in the anti-PLA2R-positive group had significantly higher levels of total cholesterol and low-density lipoprotein than those in the anti-PLA2R-negative group. No significant difference was observed in the anti-PLA2R Ab titer between patients with and without TE. Patients with TE were significantly older than those without TE.</p><p><strong>Conclusion: </strong>This study demonstrates that the positive status of anti-PLA2R Abs contributes to thrombosis formation in IMN.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Kidney Disease in Oncology: A New Concept to Enhance the Understanding of the Impact of Kidney Injury in Patients with Cancer. 肿瘤学中的急性肾病:癌症患者急性肾病:加强对肾损伤影响认识的新概念。
IF 2.3 4区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI: 10.1159/000540908
Matteo Floris, Francesco Trevisani, Andrea Angioi, Nicola Lepori, Mariadelina Simeoni, Gianfranca Cabiddu, Antonello Pani, Mitchell Howard Rosner

Background: Cancer patients are prone to developing acute kidney disease (AKD), yet this phenomenon remains understudied compared to acute kidney injury (AKI). AKD, which often develops insidiously, can cause treatment interruptions, extended hospital stays, and increased mortality.

Summary: This perspective article explores the intricate relationship between AKD and cancer, focusing on prevalence, risk factors, implications for anticancer therapy, and long-term outcomes, including chronic kidney disease progression.

Key messages: To emphasize the importance of early detection and intervention, this work advocates for increased research and awareness among clinicians to improve patient outcomes and manage healthcare burdens associated with AKD in cancer patients.

背景癌症患者容易患急性肾病(AKD),但与急性肾损伤(AKI)相比,对这一现象的研究仍然不足。急性肾病通常起病隐匿,可导致治疗中断、住院时间延长和死亡率升高。摘要 这篇透视文章探讨了急性肾脏病与癌症之间错综复杂的关系,重点关注发病率、风险因素、对抗癌治疗的影响以及长期结果,包括慢性肾脏病进展。关键信息 为强调早期发现和干预的重要性,本论文提倡加强研究并提高临床医生的认识,以改善患者的预后并控制与癌症患者 AKD 相关的医疗负担。
{"title":"Acute Kidney Disease in Oncology: A New Concept to Enhance the Understanding of the Impact of Kidney Injury in Patients with Cancer.","authors":"Matteo Floris, Francesco Trevisani, Andrea Angioi, Nicola Lepori, Mariadelina Simeoni, Gianfranca Cabiddu, Antonello Pani, Mitchell Howard Rosner","doi":"10.1159/000540908","DOIUrl":"10.1159/000540908","url":null,"abstract":"<p><strong>Background: </strong>Cancer patients are prone to developing acute kidney disease (AKD), yet this phenomenon remains understudied compared to acute kidney injury (AKI). AKD, which often develops insidiously, can cause treatment interruptions, extended hospital stays, and increased mortality.</p><p><strong>Summary: </strong>This perspective article explores the intricate relationship between AKD and cancer, focusing on prevalence, risk factors, implications for anticancer therapy, and long-term outcomes, including chronic kidney disease progression.</p><p><strong>Key messages: </strong>To emphasize the importance of early detection and intervention, this work advocates for increased research and awareness among clinicians to improve patient outcomes and manage healthcare burdens associated with AKD in cancer patients.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does Physical Exercise Ameliorate Chronic Kidney Disease-Related Complications? The Case of Anaemia and Chronic Kidney Disease-Mineral Bone Disorder. 体育锻炼能改善与 CKD 相关的并发症吗?以贫血和 CKD-MBD 为例。
IF 2.3 4区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 Epub Date: 2024-09-06 DOI: 10.1159/000540659
Filippo Aucella, Maria Amicone, Aurora Del Mar Perez Ys, Francesco Aucella, Giuseppe Gatta, Michele Antonio Prencipe, Eleonora Riccio, Ivana Capuano, Antonio Pisani, Yuri Battaglia

Background: Physical exercise (PE) can regulate inflammation, cardiovascular health, sarcopenia, anaemia, and bone health in the chronic kidney disease (CKD) population. Experimental and clinical studies both help us better understand the mechanisms that underlie the beneficial effects of the exercise, especially in renal anaemia and CKD-mineral bone disorders (CKD-MBDs). Here, we summarize this evidence, exploring the biological pathways involved, locally released substances, and crosstalk between tissues, but also the shortcomings of current knowledge.

Summary: Anaemia: Both in healthy and CKD subjects, PE may mimic hypoxia, inhibiting PHDs; so hydroxylate HIF-α subunits may be translocated into the nucleus, resulting in dimerization of HIF-1α and HIF-1β, recruitment of p300 and CBP, and ultimately, binding to HREs at target genes to cause activation. However, in CKD subjects acute PE causes higher levels of lactate, leading to iron restriction by upregulating hepatic hepcidin expression, while chronic PE allows an increased lactate clearance and HIF-α and VEGFα levels, stimulating both erythropoiesis and angiogenesis.

Ckd-mbd: PE may improve bone health decreasing bone resorption and increasing bone formation throughout at least three main pathways: (a) increasing osteoprotegerin and decreasing RANKL system; (b) decreasing cytokine levels; and (c) stimulating production of myokines and adipokines.

Key messages: Future research needs to be defined to develop evidence-based exercise guidance to provide optimal benefit for CKD using exercise interventions as adjuvant therapy for CKD-related complications such as anaemia and CKD-MBD.

背景体育锻炼(PE)可以调节慢性肾脏病(CKD)人群的炎症、心血管健康、肌肉疏松症、贫血和骨骼健康。实验和临床研究都有助于我们更好地了解运动的有益作用机制,尤其是在肾性贫血和 CKD-矿物质骨病(CKD-MBD)中。在此,我们总结了这些证据,探讨了其中涉及的生物途径、局部释放的物质和组织间的相互影响,同时也指出了现有知识的不足之处。主要发现 贫血--无论是健康人还是 CKD 受试者,PE 都可能模拟缺氧,抑制 PHDs;因此,羟基 HIF-α 亚基可能被转运到细胞核,导致 HIF-1α 和 HIF1β二聚化,招募 p300 和 CBP,最终与靶基因的 HREs 结合,引起激活。然而,在 CKD 受试者中,急性 PE 会导致乳酸水平升高,从而通过上调肝脏肝磷脂蛋白的表达来限制铁的生成;而慢性 PE 则会增加乳酸的清除率以及 HIF-α 和 VEGFα 的水平,从而刺激红细胞生成和血管生成。CKD-MBD -PE 可通过至少三种主要途径改善骨骼健康,减少骨吸收,增加骨形成:A)增加骨保护素,降低 RANKL 系统;B)降低细胞因子水平;C)刺激 miokines 和 adipokines 的产生。结论 今后的研究需要明确制定循证运动指导,利用运动干预作为辅助疗法,治疗与 CKD 相关的并发症,如贫血和 CKD-MBD,从而为 CKD 带来最佳益处。
{"title":"Does Physical Exercise Ameliorate Chronic Kidney Disease-Related Complications? The Case of Anaemia and Chronic Kidney Disease-Mineral Bone Disorder.","authors":"Filippo Aucella, Maria Amicone, Aurora Del Mar Perez Ys, Francesco Aucella, Giuseppe Gatta, Michele Antonio Prencipe, Eleonora Riccio, Ivana Capuano, Antonio Pisani, Yuri Battaglia","doi":"10.1159/000540659","DOIUrl":"10.1159/000540659","url":null,"abstract":"<p><strong>Background: </strong>Physical exercise (PE) can regulate inflammation, cardiovascular health, sarcopenia, anaemia, and bone health in the chronic kidney disease (CKD) population. Experimental and clinical studies both help us better understand the mechanisms that underlie the beneficial effects of the exercise, especially in renal anaemia and CKD-mineral bone disorders (CKD-MBDs). Here, we summarize this evidence, exploring the biological pathways involved, locally released substances, and crosstalk between tissues, but also the shortcomings of current knowledge.</p><p><strong>Summary: </strong>Anaemia: Both in healthy and CKD subjects, PE may mimic hypoxia, inhibiting PHDs; so hydroxylate HIF-α subunits may be translocated into the nucleus, resulting in dimerization of HIF-1α and HIF-1β, recruitment of p300 and CBP, and ultimately, binding to HREs at target genes to cause activation. However, in CKD subjects acute PE causes higher levels of lactate, leading to iron restriction by upregulating hepatic hepcidin expression, while chronic PE allows an increased lactate clearance and HIF-α and VEGFα levels, stimulating both erythropoiesis and angiogenesis.</p><p><strong>Ckd-mbd: </strong>PE may improve bone health decreasing bone resorption and increasing bone formation throughout at least three main pathways: (a) increasing osteoprotegerin and decreasing RANKL system; (b) decreasing cytokine levels; and (c) stimulating production of myokines and adipokines.</p><p><strong>Key messages: </strong>Future research needs to be defined to develop evidence-based exercise guidance to provide optimal benefit for CKD using exercise interventions as adjuvant therapy for CKD-related complications such as anaemia and CKD-MBD.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Construction and Validation of a Risk Prediction Model for Mild Cognitive Impairment in Non-Dialysis Chronic Kidney Disease Patient. 非透析慢性肾病患者轻度认知功能障碍风险预测模型的构建与验证
IF 2.3 4区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 Epub Date: 2024-07-17 DOI: 10.1159/000540025
Wenbin Xu, Qin Yang, Lin Li, Yuhe Xiang, Qian Yang

Introduction: The aims of this study are to explore the factors affecting mild cognitive impairment in patients with chronic kidney disease (CKD) who are not undergoing dialysis and to construct and validate a nomogram risk prediction model.

Methods: Using a convenience sampling method, 383 non-dialysis CKD patients from two tertiary hospitals in Chengdu were selected between February 2023 and August 2023 to form the modeling group. The patients were divided into a mild cognitive impairment group (n = 192) and a non-mild cognitive impairment group (n = 191), and factors such as demographics, disease data, and sleep disorders were compared between the two groups. Univariate and multivariate binary logistic regression analyses were used to identify independent influencing factors, followed by collinearity testing, and construction of the regression model. The final risk prediction model was presented through a nomogram and an online calculator, with internal validation using Bootstrap sampling. For external validation, 137 non-dialysis CKD patients from another tertiary hospital in Chengdu were selected between October 2023 and December 2023.

Results: In the modeling group, 192 (50.1%) of the non-dialysis CKD patients developed mild cognitive impairment, and in the validation group, 56 (40.9%) patients developed mild cognitive impairment, totaling 248 (47.7%) of all sampled non-dialysis CKD patients. Age, educational level, Occupation status, Use of smartphone, sleep disorders, hemoglobin, and platelet count were independent factors influencing the occurrence of mild cognitive impairment in non-dialysis CKD patients (all p < 0.05). The model evaluation showed an area under the ROC curve of 0.928, 95% CI (0.902, 0.953) in the modeling group, and 0.897, 95% CI (0.844, 0.950) in the validation group. The model's Youden index was 0.707, with an optimal cutoff value of 0.494, sensitivity of 0.853, and specificity of 0.854, indicating good predictive performance; calibration curves, Hosmer-Lemeshow test, and clinical decision curves indicated good calibration and clinical benefit. Internal validation results showed a consistency index (C-index) of 0.928, 95% CI (0.902, 0.953).

Conclusion: The risk prediction model developed in this study shows excellent performance, demonstrating significant predictive potential for early screening of mild cognitive impairment in non-dialysis CKD patients. The application of this model will provide a reference for healthcare professionals, helping them formulate more targeted intervention strategies to optimize patient treatment and management outcomes.

引言探讨影响非透析慢性肾脏病患者轻度认知障碍的因素,并构建和验证一个提名图风险预测模型:方法:采用方便抽样法,在 2023 年 2 月至 2023 年 8 月期间,从成都两家三级医院选取 383 名非透析慢性肾脏病(CKD)患者组成模型组。将患者分为轻度认知障碍组(192 人)和非轻度认知障碍组(191 人),并对两组患者的人口统计学、疾病数据和睡眠障碍等因素进行比较。采用单变量和多变量二元逻辑回归分析来确定独立的影响因素,然后进行共线性测试并构建回归模型。最终的风险预测模型通过提名图和在线计算器进行展示,并使用 Bootstrap 抽样进行内部验证。为了进行外部验证,在2023年10月至2023年12月期间,从成都另一家三甲医院选取了137名非透析的CKD患者:在建模组中,192 名(50.1%)非透析 CKD 患者出现了轻度认知障碍,在验证组中,56 名(40.9%)患者出现了轻度认知障碍,总计 248 名(47.7%)非透析 CKD 患者出现了轻度认知障碍。年龄、教育程度、职业状况、使用智能手机、睡眠障碍、血红蛋白和血小板计数是影响非透析型 CKD 患者发生轻度认知障碍的独立因素(均为 P<0.05)。模型评估显示,建模组的 ROC 曲线下面积为 0.928,95%CI(0.902,0.953);验证组的 ROC 曲线下面积为 0.897,95%CI(0.844,0.950)。该模型的 Youden 指数为 0.707,最佳临界值为 0.494,灵敏度为 0.853,特异度为 0.854,显示出良好的预测性能;校准曲线、Hosmer-Lemeshow 检验和临床决策曲线显示出良好的校准和临床效益。内部验证结果显示,一致性指数(C-index)为 0.928,95%CI (0.902, 0.953):本研究开发的风险预测模型性能卓越,在早期筛查非透析慢性肾病患者的轻度认知障碍方面具有显著的预测潜力。该模型的应用将为医护人员提供参考,帮助他们制定更有针对性的干预策略,优化患者的治疗和管理效果。
{"title":"Construction and Validation of a Risk Prediction Model for Mild Cognitive Impairment in Non-Dialysis Chronic Kidney Disease Patient.","authors":"Wenbin Xu, Qin Yang, Lin Li, Yuhe Xiang, Qian Yang","doi":"10.1159/000540025","DOIUrl":"10.1159/000540025","url":null,"abstract":"<p><strong>Introduction: </strong>The aims of this study are to explore the factors affecting mild cognitive impairment in patients with chronic kidney disease (CKD) who are not undergoing dialysis and to construct and validate a nomogram risk prediction model.</p><p><strong>Methods: </strong>Using a convenience sampling method, 383 non-dialysis CKD patients from two tertiary hospitals in Chengdu were selected between February 2023 and August 2023 to form the modeling group. The patients were divided into a mild cognitive impairment group (n = 192) and a non-mild cognitive impairment group (n = 191), and factors such as demographics, disease data, and sleep disorders were compared between the two groups. Univariate and multivariate binary logistic regression analyses were used to identify independent influencing factors, followed by collinearity testing, and construction of the regression model. The final risk prediction model was presented through a nomogram and an online calculator, with internal validation using Bootstrap sampling. For external validation, 137 non-dialysis CKD patients from another tertiary hospital in Chengdu were selected between October 2023 and December 2023.</p><p><strong>Results: </strong>In the modeling group, 192 (50.1%) of the non-dialysis CKD patients developed mild cognitive impairment, and in the validation group, 56 (40.9%) patients developed mild cognitive impairment, totaling 248 (47.7%) of all sampled non-dialysis CKD patients. Age, educational level, Occupation status, Use of smartphone, sleep disorders, hemoglobin, and platelet count were independent factors influencing the occurrence of mild cognitive impairment in non-dialysis CKD patients (all p &lt; 0.05). The model evaluation showed an area under the ROC curve of 0.928, 95% CI (0.902, 0.953) in the modeling group, and 0.897, 95% CI (0.844, 0.950) in the validation group. The model's Youden index was 0.707, with an optimal cutoff value of 0.494, sensitivity of 0.853, and specificity of 0.854, indicating good predictive performance; calibration curves, Hosmer-Lemeshow test, and clinical decision curves indicated good calibration and clinical benefit. Internal validation results showed a consistency index (C-index) of 0.928, 95% CI (0.902, 0.953).</p><p><strong>Conclusion: </strong>The risk prediction model developed in this study shows excellent performance, demonstrating significant predictive potential for early screening of mild cognitive impairment in non-dialysis CKD patients. The application of this model will provide a reference for healthcare professionals, helping them formulate more targeted intervention strategies to optimize patient treatment and management outcomes.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Significance of Apela in Acute Cardiorenal Insuffiency of Chronic Heart Failure. 阿佩拉对慢性心力衰竭急性心肾功能不全的临床意义。
IF 2.8 4区 医学 Q2 Medicine Pub Date : 2024-01-01 Epub Date: 2024-01-18 DOI: 10.1159/000536316
Yani Zong, Yajie Wang, Yuexin Hu, Zhi Wang

Introduction: Apela has a wide range of biological effects on the cardiovascular system, but the changes and significance of endogenous Apela in patients with chronic heart failure (CHF) and acute deterioration of cardiac and renal function are unclear.

Methods: A total of 69 patients with stable CHF combined with well-preserved renal function were enrolled and followed for 12 months. The effects of Apela on human renal glomerular endothelial cells (hRGEC), human glomerular mesangial cells (hMC), and human renal tubular epithelial cells (HK-2) were observed.

Results: Serum Apela concentration was positively correlated with NYHA class (r = 0.711) and N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration (r = 0.303) but negatively correlated with left ventricular ejection fraction (LVEF) (r = -0.374) and 6-min walk distance (r = -0.860) in patients with stable CHF. Twenty-one patients experiencing deterioration of renal and cardiac function were diagnosed with cardiorenal syndrome (CRS) during the follow-up period. In addition, the serum Apela, as well as the difference in Apela between stable and worsening phases (ΔApela), was correlated with the estimated glomerular filtration rate (eGFR) and ΔeGFR in patients with CRS. Apela significantly inhibited the upregulated expression of MCP-1 and TNF-α induced by angiotensin II (AngII) in hRGEC, hMC, and HK-2 cells. Apela inhibited the adhesion of THP-1 cells to hRGEC and promoted the tubular formation of hRGEC. Moreover, Apela enhanced the expression of MMP-9 in hMC but inhibited the upregulated expression of α-SMA and vimentin in HK-2 cells by AngII.

Conclusion: This study suggests that the level of Apela can be used to diagnose heart failure and assess the severity of cardiac dysfunction in patients with stable CHF, and its dynamic changes can be used to evaluate the damage to renal function in patients with CRS. Apela plays multiple protective effects on renal cells, highlighting its clinical application prospect in the prevention and treatment of CRS.

导言:Apela对心血管系统具有广泛的生物学效应,但慢性心力衰竭(CHF)和心肾功能急性恶化患者内源性Apela的变化和意义尚不清楚:方法:共招募了 69 名病情稳定且肾功能保持良好的 CHF 患者,并对其进行了为期 12 个月的随访。观察阿培拉对人肾小球内皮细胞(hRGEC)、人肾小球系膜细胞(hGMC)和人肾小管上皮细胞(HK-2)的影响:结果:在病情稳定的 CHF 患者中,血清 Apela 浓度与 NYHA 分级(r = 0.711)和 N 端前脑钠尿肽(NT-proBNP)浓度(r = 0.303)呈正相关,但与左室射血分数(LVEF)(r = -0.374)和 6 分钟步行距离(r = -0.860)呈负相关。在随访期间,21 名肾功能和心功能恶化的患者被诊断为心肾综合征(CRS)。此外,CRS患者的血清Apela以及稳定期和恶化期的Apela差值(ΔApela)与估计肾小球滤过率(eGFR)和ΔeGFR相关。Apela能明显抑制血管紧张素II(AngII)诱导的MCP-1和TNF-α在hRGEC、hGMC和HK-2细胞中的上调表达。Apela 可抑制 THP-1 细胞与 hRGEC 的粘附,并促进 hRGEC 小管的形成。此外,Apela 能增强 hGMC 中 MMP-9 的表达,但抑制了 AngII 对 HK-2 细胞中 α-SMA 和波形蛋白表达的上调:本研究表明,Apela水平可用于诊断心衰和评估稳定型CHF患者心功能不全的严重程度,其动态变化可用于评估CRS患者肾功能的损伤。Apela对肾脏细胞具有多重保护作用,在预防和治疗CRS方面具有广阔的临床应用前景。
{"title":"Clinical Significance of Apela in Acute Cardiorenal Insuffiency of Chronic Heart Failure.","authors":"Yani Zong, Yajie Wang, Yuexin Hu, Zhi Wang","doi":"10.1159/000536316","DOIUrl":"10.1159/000536316","url":null,"abstract":"<p><strong>Introduction: </strong>Apela has a wide range of biological effects on the cardiovascular system, but the changes and significance of endogenous Apela in patients with chronic heart failure (CHF) and acute deterioration of cardiac and renal function are unclear.</p><p><strong>Methods: </strong>A total of 69 patients with stable CHF combined with well-preserved renal function were enrolled and followed for 12 months. The effects of Apela on human renal glomerular endothelial cells (hRGEC), human glomerular mesangial cells (hMC), and human renal tubular epithelial cells (HK-2) were observed.</p><p><strong>Results: </strong>Serum Apela concentration was positively correlated with NYHA class (r = 0.711) and N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration (r = 0.303) but negatively correlated with left ventricular ejection fraction (LVEF) (r = -0.374) and 6-min walk distance (r = -0.860) in patients with stable CHF. Twenty-one patients experiencing deterioration of renal and cardiac function were diagnosed with cardiorenal syndrome (CRS) during the follow-up period. In addition, the serum Apela, as well as the difference in Apela between stable and worsening phases (ΔApela), was correlated with the estimated glomerular filtration rate (eGFR) and ΔeGFR in patients with CRS. Apela significantly inhibited the upregulated expression of MCP-1 and TNF-α induced by angiotensin II (AngII) in hRGEC, hMC, and HK-2 cells. Apela inhibited the adhesion of THP-1 cells to hRGEC and promoted the tubular formation of hRGEC. Moreover, Apela enhanced the expression of MMP-9 in hMC but inhibited the upregulated expression of α-SMA and vimentin in HK-2 cells by AngII.</p><p><strong>Conclusion: </strong>This study suggests that the level of Apela can be used to diagnose heart failure and assess the severity of cardiac dysfunction in patients with stable CHF, and its dynamic changes can be used to evaluate the damage to renal function in patients with CRS. Apela plays multiple protective effects on renal cells, highlighting its clinical application prospect in the prevention and treatment of CRS.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139491628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physical Exercise in Kidney Renal Recipients: Where Have We Come? 肾移植受者的体育锻炼:我们走到了哪一步?
IF 2.3 4区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 Epub Date: 2024-06-27 DOI: 10.1159/000539996
Giovanni Mosconi, Valentina Totti, Gianluigi Sella, Giulio Sergio Roi, Alessandro Nanni Costa, Lia Bellis, Massimo Cardillo

Background: Kidney transplantation constitutes the most effective therapeutic option for patients suffering from end-stage renal disease but remains burdened by a high incidence of cardiovascular disease. To date, exercise is an important preventive strategy that has been underestimated; in kidney transplant patients, exercise programs lead to an improvement in cardiorespiratory performance, muscle strength, arterial stiffness, and patients' quality of life perception.

Summary: The nephrology and transplant community have moved from generic suggestions to specific indications regarding frequency, intensity, time, type, volume, and progression of physical exercise both in the pre- and posttransplant phase. The latest guidelines from the World Health Organization for patients with chronic conditions propose a combination of aerobic, muscle-strengthening, and multicomponent exercises (e.g., balance) to improve health. Based on recent evidence, a combined exercise program (aerobic and strength exercise) is largely proposed to kidney transplant recipients. Aerobic exercise should be performed at an intensity >60% of theoretical maximum heart rate or maximum oxygen uptake possibly every day, and strength training should be performed at a >60% the estimate single maximum repetition, at least 2 times per week.

Key messages: Physical exercise should be personalized in relation to the patient's baseline performance; increases must be progressive and gradual. Regular physical activity should also be recommended to patients awaiting for a transplant. Eventually, organizational models based on a network of nephrology units, transplant centers, sports medicine centers, and fitness center or outdoor gym are essential elements for overcoming the logistical barriers for prescribing and carrying out regular physical activity.

背景 肾移植是终末期肾病患者最有效的治疗方法,但心血管疾病的发病率居高不下。迄今为止,运动是一种重要的预防策略,但却被低估了;在肾移植患者中,运动计划可改善心肺功能、肌肉力量、动脉僵化和患者的生活质量感知。小结 肾脏病学和移植学界已经从一般性建议转变为关于移植前和移植后阶段体育锻炼的频率、强度、时间、类型、量和进展的具体指示。世界卫生组织针对慢性病患者的最新指南建议将有氧运动、肌肉强化运动和多成分运动(如平衡运动)结合起来,以改善健康状况。根据最近的证据,肾移植受者大多建议进行综合锻炼计划(有氧运动和力量锻炼)。有氧运动的强度应达到理论最大心率或最大摄氧量的 60%,每周至少 2 次;力量训练的强度应达到估计单次最大重复次数的 60%。关键信息 体育锻炼应根据患者的基线表现进行个性化设计;运动量的增加必须循序渐进。还应建议等待移植手术的患者定期进行体育锻炼。最终,建立在肾病科、移植中心、运动医学中心和健身中心或室外健身房网络基础上的组织模式,是克服规定和开展定期体育锻炼的后勤障碍的基本要素。
{"title":"Physical Exercise in Kidney Renal Recipients: Where Have We Come?","authors":"Giovanni Mosconi, Valentina Totti, Gianluigi Sella, Giulio Sergio Roi, Alessandro Nanni Costa, Lia Bellis, Massimo Cardillo","doi":"10.1159/000539996","DOIUrl":"10.1159/000539996","url":null,"abstract":"<p><strong>Background: </strong>Kidney transplantation constitutes the most effective therapeutic option for patients suffering from end-stage renal disease but remains burdened by a high incidence of cardiovascular disease. To date, exercise is an important preventive strategy that has been underestimated; in kidney transplant patients, exercise programs lead to an improvement in cardiorespiratory performance, muscle strength, arterial stiffness, and patients' quality of life perception.</p><p><strong>Summary: </strong>The nephrology and transplant community have moved from generic suggestions to specific indications regarding frequency, intensity, time, type, volume, and progression of physical exercise both in the pre- and posttransplant phase. The latest guidelines from the World Health Organization for patients with chronic conditions propose a combination of aerobic, muscle-strengthening, and multicomponent exercises (e.g., balance) to improve health. Based on recent evidence, a combined exercise program (aerobic and strength exercise) is largely proposed to kidney transplant recipients. Aerobic exercise should be performed at an intensity &gt;60% of theoretical maximum heart rate or maximum oxygen uptake possibly every day, and strength training should be performed at a &gt;60% the estimate single maximum repetition, at least 2 times per week.</p><p><strong>Key messages: </strong>Physical exercise should be personalized in relation to the patient's baseline performance; increases must be progressive and gradual. Regular physical activity should also be recommended to patients awaiting for a transplant. Eventually, organizational models based on a network of nephrology units, transplant centers, sports medicine centers, and fitness center or outdoor gym are essential elements for overcoming the logistical barriers for prescribing and carrying out regular physical activity.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Kidney & blood pressure research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1